Meta-analysis of 7 RCTs (6734 adults with migraine): single-dose rimegepant 75 mg increased 2-h pain freedom vs placebo (19.8% vs 10.7%; RR 1.93; NNT 10) and sustained 2-24 h pain freedom (14.2% vs 6.3%). Adverse events 14.3% vs 12.7%.
Meta-analysisn = 6,734
Istoc et al. Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis